erlizumab
mAbexperimental
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Mechanism of action
- Integrin beta-2INHIBITOR
ITGB2 inhibitor
- Integrin beta-2NEGATIVE MODULATOR
ITGB2 negative modulator
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109496 ↗
- ChEMBLCHEMBL2109095 ↗
Also known as
- erlizumab
- mln-01
- rhumab cd18